J. Marty Tenenbaum, PhD, Chairman
Marty Tenenbaum is a renowned computer scientist, Internet entrepreneur and cancer survivor. He founded Cancer Commons and CollabRx (NASD: CRLX) to help each cancer patient obtain the best possible outcome. He is an Internet commerce pioneer and visionary, having founded EIT (1990) and CommerceNet (1994) to accelerate business use of the Internet, and later, was an officer and director of Commerce One, Webify Solutions (sold to IBM in 2006), and Medstory (sold to Microsoft in 2007). He currently serves on the boards of Efficient Finance, Patients Like Me, and the Public Library of Science (PLoS).
Dr. Tenenbaum is a fellow and former board member of the Association for the Advancement of Artificial Intelligence (AAAI), and a former consulting professor of Computer Science at Stanford. He holds B.S. and M.S. degrees in Electrical Engineering and Computer Science from MIT, and a Ph.D. from Stanford.
Mikhail Gishizky, PhD
Mikhail Gishizky has more than 25 years experience in research and development within the academic, biotechnology, and pharmaceutical industry settings where he led efforts in the development of revolutionary signal transduction inhibitor drugs for the treatment of cancer and other diseases. Mikhail has been instrumental in establishing two biotechnology companies (SUGEN, Entelos) whose technology is helping bring the promise of personalized medicine to the patient’s bedside. He has been a member of the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation where he contributed to numerous workshops and publications regarding pharmaceutical development and patient care that have been used by public and Congressional leaders to support the call for change in the biomedical enterprise.
Earlier in his career, Mikhail held positions of increasing responsibility at SUGEN, Pharmacia, and Pfizer as Vice President and Research Zone Head, developing targeted therapies and signal transduction pathway analysis tools to identify patients most likely to respond to given therapies (ie, Sutent, a leader in the class of signal transduction inhibitors marketed by Pfizer). Dr. Gishizky received his degree in endocrinology at the University of California, San Francisco, where his work focused on defining the molecular mechanisms responsible for the development and progression of diabetes mellitus. His postdoctoral training and academic work focused on cancer biology, hematopoietic cell development. His research led to the development of in vitro systems and an animal model for human chronic myeloid leukemia that was instrumental in the development of Gleevec. Mikhail has published extensively in the areas of diabetes mellitus and oncology research.
Laurence J. Marton, MD
Dr. Marton serves as a consultant to industry and to nonprofit, governmental, and academic institutions. In the nonprofit sector, Dr. Marton serves on the Board of Trustees of the American Association for Cancer Research Foundation, and on the Board of Directors of Cancer Commons, Rapid Science, and the Bay Area American Committee for the Weizmann Institute of Science. In the for-profit sector, he serves on the Board of Directors of TOMA Biosciences, RenovoRx, Microsonic Systems and Pathologica, is Chair of the Scientific Advisory Board of PharmaJet, is on the Advisory Boards of Gem Pharmaceuticals, Gliimpse, Matternet, and Silicom Ventures, and on the Editorial Board of the Journal of Precision Medicine.
Previously, Dr. Marton was Dean of the University of Wisconsin Medical School and Chaired the Department of Laboratory Medicine at UCSF, where he was a Professor in the Departments of Laboratory Medicine and Neurological Surgery. He is an expert in the fields of cell growth and drug development. His research has resulted in more than 195 original publications, 60 scientific reviews and chapters, four books, and numerous patents.
Dr. Marton received his MD from the Albert Einstein College of Medicine and his BA from Yeshiva University.
Frank McCormick, PhD, FRS, DSc (Hon)
Frank McCormick, PhD, FRS, DSc (Hon), was Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization that is one of the largest cancer centers in the Western U.S, and he was also Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his BSc in biochemistry from the University of Birmingham (1972) and his PhD in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the U.S at the State University of New York at Stony Brook and in London, UK, at the Imperial Cancer Research Fund. He has been a fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice-President of Research, 1990-91) and Chiron Corporation, where he was a vice-president of research from 1991-92. In 1992, he founded Onyx Pharmaceuticals and served as its chief scientific officer until 1996. Dr. McCormick’s current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies. In addition to his positions held at UCSF, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF’s Department of Microbiology and Immunology. Dr. McCormick is the author of more than 270 scientific publications.
Gladys H. Monroy, PhD, JD
Gladys Monroy is Senior Partner at Morrison Foerster. Her practice includes strategic counseling, comprehensive patent portfolio management, interferences, reexaminations, and reissues. Dr. Monroy represents companies of all sizes in the areas of patent prosecution and technology transfers, involving many technologies within the field of life science. Dr. Monroy has previously held numerous leadership positions in intellectual property law associations, such as President and Board of Directors member of the Silicon Valley Intellectual Property Law Association, and Executive Committee member of the California State Bar Intellectual Property Section. She has received many honors, including being elected to the IP Law & Business Patent Prosecution Hall of Fame and being named by Chambers Women in Law as Intellectual Property Lawyer of the Year.
Prior to her career in law, Dr. Monroy was a post-doctoral fellow at the Einstein College of Medicine and an Assistant Professor of Microbiology at New York Medical College. She received her MS and PhD in biochemistry from NYU.
Heather Rangel is a Partner with Deloitte in San Jose, where she serves as Deloitte’s global leader for a leading technology company. In this roll, she coordinates a large cross-functional team delivering services and creating alliances to bring to market. Heather is also the Technology Sector Leader for Deloitte Tax in the U.S., building client relationships within the sector and delivering sector perspective to Deloitte professionals and clients. In her 18 years as a management consultant, she has delivered solutions to the technology, media and entertainment sectors, predominantly in the areas of global expansion, mobility of talent, international HR strategy and process improvement.
Heather is an inspirational leader, a frequent public speaker, and a strong advocate for women in business and technology.
Heather is the mother of two teenagers and that is her favorite role. She is an avid reader, competitive swimmer, adventurous traveler, and passionate supporter of the arts—especially documentary films focusing on the most important economic and social issues of our time. Heather founded the Shine Project, an initiative that continues to shine the light of those who have lost their lives to cancer through its support of Cancer Commons.
Dick Levy, retired Chairman and CEO, Varian Medical, and former Chairman, Sutter Health
Peter Yu, MD, Physician-in-Chief Hartford HealthCare Cancer Institute, Past President, American Association of Clinical Oncology
William Brody, MD, PhD, former President Johns Hopkins University, and Salk Institute
William Miller, PhD, former Provost, Stanford University, and former President, SRI International
Rob Rodin, former CEO, Marshall Industries
William Wong, PhD, former EVP and GM, Merchant Solutions Group, Net Deposit and former Executive Director, Cancer Commons
William Brody, MD, PhD, former President Johns Hopkins University, and Salk Institute